2022/03/28 News Release Ube Industries and HiLung Sign Joint Development Agreement for Co-Development of Novel Selective LPA1 Antagonist HL001 for Pulmonary Fibrosis
2022/03/23 News Release Ube Industries and Kirilys Therapeutics, Inc. Sign License Agreement for CDK7 inhibitors
2022/02/28 News Release Shionogi and Ube Industries Enter into a Strategic Development Collaboration for the Novel Anti-RS Virus Drug Candidate S-337395
2022/02/04 IR News (Presentation and Q&A Transcript) Telephone Conference for the Third Quarter of FY2021 Consolidated Result
2022/02/02 IR News Consolidated Financial Report for the First Three Quarters of the Fiscal Year Ending March 31, 2022
2021/12/24 News Release In antiplatelet agents Efient® Tablets 3.75 mg and Efient® Tablets 2.5 mg Supplemental New Drug Application Approval for Additional Indication, Dosage and Administration in Japan
2021/12/22 News Release (Revision of Disclosed Information) Ube Industries and Mitsubishi Materials Announce Change in the Amount of Capital and Timing of Name Change for Successor Company upon Company Split for Integration of Cement Businesses, etc.
2021/12/17 News Release Ube Industries Announces Absorption (Simplified Merger/Short-Form Merger) of Wholly-Owned Subsidiary Meiwa Plastic Industries, Ltd.
2021/11/02 IR News Ube Industries Selects and Applies to Be Listed on Tokyo Stock Exchange's New Prime Market Segment
2021/11/02 IR News Consolidated Financial Report for the First Half of the Fiscal Year Ending March 31, 2022
2021/11/02 IR News (Presentation and Q&A Transcript) Telephone Conference for the Second Quarter of FY2021 Consolidated Result
2021/08/03 News Release Ube Industries Modifies Plans to Split Off Synthetic Rubber Business by Establishing Wholly-Owned Subsidiary
2021/08/03 IR News Consolidated Financial Report for the First Quarter of the Fiscal Year Ending March 31, 2022